Physician profile
Sonali S Kumar
NPI 1922099308
$1,741.88
in general payments reported to CMS, 2019-2025
17 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $131 · 2021: $186 · 2022: $11.86 · 2023: $208 · 2024: $454 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $434.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $282.90 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $163.05 | 2019-2025 | Kisunla, Jardiance |
| Novo Nordisk INC | $131.59 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $106.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.48 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $99.92 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $79.91 | 2019 | |
| Pfizer INC. | $76.30 | 2019-2021 | |
| Amgen INC. | $49.79 | 2024-2025 | Repatha, Krystexxa |
| Astellas Pharma US INC | $43.51 | 2020-2021 | |
| Dexcom, INC. | $39.42 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $34.72 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.46 | 2021 | |
| Abbott Laboratories | $23.76 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.02 | 2024 | |
| Merck Sharp & Dohme LLC | $13.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.